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Talin2Using Tln1ﬂ/ﬂ;CreER mice, we show that tamoxifen-induced inactivation of the talin1 gene throughout the
embryo produces an angiogenesis phenotype that is restricted to newly forming blood vessels. The phenotype
has a rapid onset in early embryos, resulting in vessel defects by 48 h and death of the embryo within 72 h.
Very similar vascular defects were obtained using a Tie2-Cre endothelial cell-speciﬁc Tln1 knockout, a
phenotype that was rescued by expression of a Tln1mini-gene in endothelial cells. We show that endothelial
cells, unlike most other cell types, do not express talin2, which can compensate for loss of talin1, and
demonstrate for the ﬁrst time that endothelial cells in vivo lacking talin1 are unable to undergo the cell
spreading and ﬂattening required to form vessels. license.© 2010 Elsevier Inc. Open access under CC BY license.Introduction
Adhesion of animal cells to the extracellular matrix (ECM) is
essential for the development of multicellular organisms and for the
functional and structural integrity of tissues in the adult (Hynes,
2009). Cell-ECM interactions are mediated primarily by the integrin
family of cell adhesion molecules, transmembrane receptors com-
posed of an α- and β-subunit. Integrins possess a large extracellular
domain that interacts with ECM proteins and a small intracellular
domain that interacts with a wide variety of proteins inside the cell
including signalling and actin-binding proteins (Legate et al., 2009;
Moser et al., 2009). The adaptor protein talin is one of a number of
proteins that couples the cytoplasmic tail of the β-integrin subunit to
F-actin, a link that is required to transmit force from the actin
cytoskeleton to the extracellularmatrix (Critchley, 2009). However, in
addition to its structural role, talin also functions as a regulator of
integrin activity by binding to β-integrin tails in a two-step process
that alters the conformation of the integrin heterodimer and increases
its afﬁnity for extracellular ligand (Anthis et al., 2009; Shattil et al.,
2010; Wegener et al., 2007). The ability of talin to activate integrins
allows it to regulate the assembly of multi-protein adhesion and
signalling complexes (focal adhesions; FA) that are required for cell
spreading, migration and contraction (Zhang et al., 2008).Talin is a large (270 kDa) dimeric adaptor proteinmade up of an N-
terminal head domain and a long ﬂexible rod domain that can be
dissociated from each other by calpain 2 cleavage (Critchley, 2009.
The talin head comprises an atypical FERM domain (Elliott et al.,
2010) that contains the major integrin-binding site (Anthis et al.,
2009; Bouaouina et al., 2008;Wegener et al., 2007), as well as binding
sites for signalling proteins such as the type 1ϒ isoform of PIP-kinase
(Barsukov et al., 2003; Di Paolo et al., 2002; Ling et al., 2002) and also
acidic phospholipids (Anthis et al., 2009; Goult et al., 2010). The talin
rod is made up of a series of amphipathic helical bundles and contains
a second integrin-binding site of as yet undetermined function
(Gingras et al., 2009; Rodius et al., 2008), at least two actin-binding
sites (Hemmings et al., 1996) and multiple binding sites for vinculin
(Gingras et al., 2005) which itself can bind actin (Ziegler et al., 2006).
The C-terminus of the rod contains the dimerisation domain and is
required for maximal actin-binding (Gingras et al., 2008). The talin
head and rod domains also interact intra-molecularly resulting in an
autoinhibited form of the molecule that is thought to be cytoplasmic
(Goksoy et al., 2008; Goult et al., 2009). Exactly how talin becomes
activated is unclear, but there is strong evidence that this is regulated
by a Rap1A/RIAM dependent signalling pathway (Han et al., 2006; Lee
et al., 2009), and also by PIP2 (Goksoy et al., 2008).
There are two talin isoforms in vertebrates encoded by separate
genes. Talin1 is required to maintain cell spreading, for cell migration
and for FA formation (Kopp et al., 2010; Zhang et al., 2008). Talin2was
discovered following publication of the human genome sequence
(Monkley et al., 2001) and appears to be encoded by the ancestral
gene, with Tln1 arising by gene duplication just prior to the emergence
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is 74% identical and 86% similar to talin1, and both talin isoforms are
the same size and possess the same protein domains that are key to the
function of talin1. At present, it is unclearwhy vertebrates express two
such similar proteins. Evidence to date suggests that talin1 is
expressed in all cells and tissues whereas talin2 is expressed in most
but not all cell types (Debrand et al., 2009; Monkley et al., 2001;
Senetar and McCann, 2005). Studies in cultured cells have shown that
talin2 can functionally compensate for the loss of talin1 in cells that
express both isoforms (Zhang et al., 2008), and talin2 can rescue the
phenotype caused by loss of talin1 in cells where only this isoform is
expressed (Kopp et al., 2010).
Gene knockout studies in mice have provided some insight into the
roles of talin1 and talin2 at the organismal level. Constitutive knockout
of talin1 results in developmental arrest at around gastrulation sug-
gestive of an important role for this isoform in the early cell
morphogenetic events that occur during embryonic development
(Monkley et al., 2000). The severity and early onset of this phenotype
has led to the assumption that talin2 is either not expressed in the early
embryo, or performs a different role. Surprisingly, constitutive knockout
of the Tln2 gene either using a gene trap approach (Chen and Lo, 2005)
or by deletion of thewhole coding sequence produced no outward signs
of any abnormalities during the ﬁrst 18 months of life, and the mice are
fertile (Debrand et al., unpublished data). Both talin isoforms are ex-
pressed in skeletal muscle, although talin2 is the predominant isoform,
and co-localises with the β1D-integrin splice variant in myotendinous
junctions (Conti et al., 2008). Consistent with this ﬁnding, knockout of
Tln2 produces a mild form of muscular dystrophy (although this was
only apparent from histology), a phenotype that was signiﬁcantly more
severe than seen following muscle-speciﬁc deletion of Tln1. However,
knockout of both genes led to severe defects in muscle development
during embryogenesis that subsequently resulted in postnatal lethality
(Conti et al., 2009). This suggests that in skeletal muscle, the two iso-
forms have overlapping and distinct functions. Similarly, tissue-speciﬁc
inactivation of Tln1 in heart also resulted in no apparent phenotype
suggesting that compensation by talin2 may also occur in this tissue (R.
S. Ross/A.-M. Manso, personal communication). In contrast, platelets
express only talin1 and platelet-speciﬁc knockout of Tln1 leads to
spontaneous haemorrhaging and pathological bleeding (Nieswandt
et al., 2007; Petrich et al., 2007).
The aim of this study was to establish whether any other cell types
are dependent on talin1 alone, either due to lack of talin2 expression
as in platelets, or due to functional differences between the two
isoforms. To address this question, we temporally inactivated Tln1 at
different times during embryonic development using a tamoxifen-
inducible CreER allele. The resulting loss of talin1 caused severe
defects in angiogenesis without apparently affecting the development
of othermajor tissues and organs.We show that this phenotype is due
to loss of talin1 speciﬁcally from endothelial cells, which express only
talin1 and not talin2, and that the defect in angiogenesis could be
rescued by expression of an exogenous Tln1 mini-gene.
Material and methods
Antibodies
PECAM1 antibody (MEC13.3) was from BD Pharmigen. Rat anti-
endomucin (clone V7C7, Morgan et al., 1999) was a gift from Dr.
Vestweber, Max Planck, Germany. Talin1 (97 H6) and talin2 (68E7)
were generated in house (Debrand et al., 2009; Kopp et al., 2010).
Anti-vinculin antibody (F9) was from Santa Cruz.
Mouse strains and matings
All procedures on mice were performed in accordance with the
UK Animals (Scientiﬁc Procedures) Act 1986. Tln1 conditional mice(Tln1ﬂ; MGI:3770513) have been described previously (Nieswandt
et al., 2007; Petrich et al., 2007). Tie2-Cre mice (Kisanuki et al., 2001)
were generously supplied by Dr. Yuri Kotelevtsev, Edinburgh. CreER
(Hayashi andMcMahon, 2002), and ROSA26lacZ (Soriano, 1999) mice
were obtained from Jackson Labs and the CreER was activated in utero
by one IP injection of the mother with 2 mg tamoxifen in corn oil. All
mice were genotyped by PCR as described in Nieswandt et al. (2007)
and Petrich et al. (2007).
Tln1 transgenic mice were constructed using a vector consisting of
a chicken actin promoter/CMV enhancer driving the expression of a
loxP sequence-ﬂanked EGFP cDNA followed by a mouse talin1
expression cassette (Fig. 6A). The talin1 expression cassette consisted
of a mouse talin1 cDNA containing introns 2 and 3 and an amino-
terminal hemagglutinin (HA) epitope. Founder mice were identiﬁed
by PCR of genomic DNA using primers to GFP sequence (sense: 5'-
GCACGACTTCTTCAAGTCCGCCATGCC-3', antisense: 5'-CCGTTCTTC-
TGCTTGTCGGCCATGATA-3') and observation of GFP ﬂuorescence in
various tissues with a ﬂuorescence stereomicroscope (MVX10Macro-
view, Olympus). A founder line selected for ubiquitous GFP expression
and moderate, Cre-dependent HA-talin expression was crossed with
Tln1ﬂ/ﬂ;Tie2Cre mice. Embryos were collected at the ages described
based on the timing of the vaginal plug date, genotyped by PCR of yolk
sac and digital photographs were obtained using stereomicroscopy.
Whole mount embryo staining
Whole mount embryos were ﬁxed in 2% paraformaldehyde (PFA),
0.1% glutaraldehyde for 10–20 min, washed and stained for β-
galactosidase activity overnight at 37 °C in 2.5 mM X-gal, 5 mM
potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl2,
2% sodium deoxycholate and 0.4% NP-40 in phosphate buffer. For
PECAM1 immunostaining of whole embryos (with or without
attached yolk sacs), embryos were ﬁxed in 4% PFA for 2 h on ice
then permeabilized in PBX (PBS, 0.1% Triton X-100) for 3×5 min at
room temperature (RT). Embryos were dehydrated, then rehydrated
through a methanol series and blocked in 10% normal goat serum
(NGS)/PBX for 2 h RT with gentle agitation. They were then incubated
in PECAM1 antibody (1:50) in 10% NGS/PBX overnight at 4 °C with
gentle agitation followed by 5×1 h washes in PBX at RT. The washed
embryos were then incubated in goat anti-rat Alexa 488 (1:400) in
10% NGS/PBX overnight in the dark at 4 °C with gentle agitation
followed by 5×1 h washes in PBX at RT. Embryos were then post-
ﬁxed in 4% PFA in PBS for 10 min at RT and then washed in PBS.
Stained embryos and yolk sacs were photographed either on a
stereomicroscope with ﬂuorescent illumination or imaged on a Leica
TPS SP5 confocal microscope set up to detect Alexa-488 ﬂuorophore.
Deconvolution of the Z-series generated by confocal microscopy was
performed using Huygens Essential Software and Imaris64 was used
to generate both maximum intensity projections and 3D projection
movies.
Histology, immunoctyochemistry and electron microscopy
Embryos were ﬁxed in 4%PFA followed by processing for wax
embedding. Wax sections (5 μm) were de-waxed and, for histological
analysis, were stained with hematoxylin and eosin, mounted and
photographed. Sections to be used for immunohistochemistry were
treated with 3% H2O2 in PBS to inactivate endogenous peroxidases
followed by antigen retrieval using citric acid (pH 6) in a microwave
for 12 min. The sections were then cooled and blocked in 10% NGS in
PBX, then in 1:50 goat anti-mouse IgG antibody in PBS each for 1 h at
RT. Sections were then incubated with endomucin antibody (1:10) in
10% NGS/PBS for 1 h at 4 °C, followed by 3×10 min washes in PBX,
and then incubated with 1:200 biotin conjugated anti-rat secondary
(BD Pharmingen) for 20 min at RT followed by washing for 3×10 min
in PBX. Detection was performed by incubation in 1:500 streptavidin
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washing for 3×10 min in PBX and visualisation using Vector Labs DAB
substrate kit. Sections were then lightly counterstained with haema-
toxylin, mounted and photographed (Leica DM5000B with DFC420C
camera attachment).
Embryos to be analysed by EM were stained for β-gal as described
above, ﬁxed in 1% osmium tetroxide/PBS for 1 h, washed 3×20 min in
distilled de-ionised water and processed through an ethanol series
into 100% ethanol. Embryos were incubated in propylene oxide for
2×15 min then 50:50 propylene oxide/Spurr's resin (original formu-
lation) for 2 h. The propylene oxide was allowed to slowly evaporate
overnight and then replaced with fresh resin and incubated for 2 h
(x2). Samples were placed into moulds and resin polymerised at 60 °C
for 16 h. Embedded samples were remounted and sectioned trans-
versely using a Reichert Ultracut S ultramicrotome. Thin sections of
approximately 80 nm thickness were cut from each sample and
collected onto copper mesh grids. The sections were counterstained
with 2% Uranyl acetate for 20 min, followed by 4 min in Reynold's lead
citrate. Sampleswere viewed on a JEOL 1220 TEMwith an accelerating
voltage of 80 kV. Images were captured using a Mageview III digital
camera with Analysis software.
Endothelial and ﬁbroblast cell isolation and culture, staining and
Western blotting
Mouse lung endothelial cells (MLEC) or embryonic endothelial
cells were isolated and cultured according to Reynolds and Hodivala-
Dilke (2006). Embryo ﬁbroblasts were isolated and cultured according
to Hüser et al. (2001). To activate CreER in cultured cells, 100 nM
4-hydroxy tamoxifen (4OHT) (or for controls the equivalent volume
of ethanol) was added to the culture media at the time of plating and
this was replaced 18–24 h later with fresh media. Western blotting
was performed as previously described (Kopp et al., 2010). Cells
plated onto ﬁbronectin were stained with antibodies to talin1 (97
H6) or talin2 (68E7), PECAM1 and/or actin (Kopp et al., 2010).
Results
Inactivation of talin1 in mouse embryos leads to defects in angiogenesis
To investigate the role of talin1 in development of the post-
gastrulation mouse embryo we crossed mice carrying the tamoxifen-
inducible CreER transgene (Hayashi and McMahon, 2002) to
conditional Tln1 mice (Petrich et al., 2007; Nieswandt et al., 2007)
to generate Tln1ﬂ/ﬂ;CreER embryos, and induced global Tln1 inactiva-
tion in utero by maternal injection of tamoxifen. Littermates of other
genotypes (e.g., Tln1ﬂ/+;CreER) were used as controls. We also
generated mice carrying the ROSA26 lacZ reporter (Soriano, 1999)
to conﬁrm that administration of tamoxifen to pregnant females
efﬁciently activated CreER in embryos. As expected, tamoxifen-
induced widespread expression of β-gal throughout the embryo
(Fig. 1A). To demonstrate that Cre activation led to loss of talin1, we
treated Tln1ﬂ/ﬂ;CreER mouse embryonic ﬁbroblasts with 4-hydro-
xytamoxifen (4OHT); after 96 h very little talin1 was detectable
compared to controls (Fig. 1B).
In the initial experiments, tamoxifen was injected into 8.5 dpc
pregnant females and the embryos collected 24 or 48 h later. No
phenotype was observed in Tln1ﬂ/ﬂ;CreER embryos collected at 24 h
(n=7; not shown). However, the 10.5 dpc Tln1ﬂ/ﬂ;CreER embryos
collected 48 h after tamoxifen administration (referred to as 8.5/10.5
embryos) exhibited abnormal blood pooling at sites throughout the
embryo (Fig. 1C). A similar phenotype was observed in 9.5/11.5
embryos (Fig. S1A). No such phenotype was observed in controls
(Fig. 1C), or in embryos of any genotypewhere themotherwas injected
with corn oil vehicle instead of tamoxifen (not shown), indicating that
thephenotype is associated speciﬁcallywith the tamoxifen-induced lossof Tln1. If the 8.5/10.5 embryos were left for a further 24 h (total of 72 h
post tamoxifen) to 11.5 dpc (8.5/11.5; n=6) all embryos died, some
exhibiting signs of severe haemorrhaging (Fig. 1D).
When tamoxifen was administered earlier, at approximately
7.0 dpc, and embryos examined 48 h later at 9.0 dpc (n=8), the
blood pools were severe and conﬁned mainly to the head (Fig. 1E).
The fact that maternal injection of tamoxifen at 7.0 dpc produced an
early phenotype was unexpected since the placental connection
between embryo and mother has not yet been established. We
assume that the tamoxifen reached the embryo by diffusion across the
yolk sac. In contrast, if tamoxifen is not administrated until 10.5 dpc
and embryos collected 48 h later (10.5/12.5), the Tln1ﬂ/ﬂ;CreER em-
bryos showed a very mild phenotype with only a few small bleeds
visible on the surface of the head (Fig. 1F). Similar results were
observed for 11.5/13.5 dpc and 12.5/14.5 dpc CreER embryos (not
shown). Sectioning of 10.5/12.5 embryos showed that all the major
structures and organs were present and appeared normal in both size
andmorphology, although localised haemorrhagingwas observed in a
range of tissues including lung, ganglion VII (Fig. 1F), head
mesenchyme and neuroepithelium (not shown).
To investigate the cause of the blood pooling/haemorrhaging in
8.5/10.5 dpc mutant embryos, they were sectioned and the blood
vessels identiﬁed by staining for the endothelial cell marker
endomucin (Morgan et al., 1999). The sections showed a reduction
in the number of vessels, and those that were present were often
irregularly shaped and sized, and often packed full with blood cells
(Fig. 2A d; *), something never observed in control vessels (Fig. 2A a,
c). There was also evidence of haemorrhaging (Fig. 2A d; arrowhead),
and some vessels were not completely enclosed by endothelial cells
(arrow).Wholemount staining of the 8.5/10.5 embryos for the vessel-
speciﬁc protein PECAM1 (CD31) demonstrated a severely defective
vascular structure throughout the mutant embryos. While the control
8.5/10.5 dpc embryo had a hierarchical network of regularly branch-
ing vessels (Fig. 2B a, c), the vessels of the mutant embryos were
frequently dilated (Fig. 2B b, d; open arrowhead) and discontinuous,
often ending abruptly in sac-like structures (arrow). They also
displayed reduced branching and therefore decreased vascularisation
of the surrounding tissues, and it appeared that some endothelial cells
were not organised into vessels (Fig. 2B b; arrowhead). The above
data point to an apparent defect in angiogenesis in Tln1ﬂ/ﬂ;CreER
embryos exposed to tamoxifen.
Interestingly, the angiogenesis defect was the only phenotype
observed in the 48 h following tamoxifen administration despite the
fact that it would be expected to inactivate Tln1 throughout the
embryo. The other surprising observation is that the phenotype occurs
so rapidly, i.e., within 48 h following exposure to tamoxifen. In
cultured cells, at least 72–96 h are required after 4-hydroxy tamoxifen
(4OHT) treatment before talin1 protein levels are low enough for
defects in cell spreading to become apparent (Fig. S1B,C; Kopp et al.,
2010). Trypsinisation and replating of cells to facilitate turnover of FA
further reduces talin1 protein levels and increases the severity of the
phenotype (Fig. S1C).
Endothelial-speciﬁc inactivation of Tln1 also results in angiogenesis
defects
Angiogenesis defects in embryos arise from deletion of a number
of cell adhesion genes (Braren et al., 2006; Carlson et al., 2008; George
et al., 1997; Proctor et al., 2005). In many cases this is due to defective
endothelial cells, but in others it has been attributed to defects in the
surrounding parenchymal cells or pericytes (Proctor et al., 2005; Silva
et al., 2008). To assess the contribution of talin1 depletion from
endothelial cells to the observed phenotype, we crossed Tln1ﬂ/ﬂ mice
to the endothelial cells-speciﬁc Cre line, Tie2-Cre (Kisanuki et al.,
2001), to generate Tln1ﬂ/ﬂ;Tie2-Cre mice (referred to as Tie2-Cre
mutants) in which Tln1 is inactivated in endothelial cells and some
Fig. 1. Tamoxifen-induced deletion of Tln1 in mouse embryos results in widespread bleeding. (A) 10.5 dpc Tln1ﬂ/ﬂ;CreER embryo possessing the ROSA26 lacZ reporter exposed to
tamoxifen in utero 48 h earlier (left panel) followed by staining with X-gal (right panel). (B) Mouse embryo ﬁbroblasts of the genotypes shown were treated with 4OHT, and 96 h
later cell lysates were blotted and probed with talin1 antibody 97 H6. Vinculin was used as a loading control. (C) Examples of 10.5 dpc embryos of genotypes shown exposed to
tamoxifen in utero 48 h earlier at 8.5 dpc. Arrows indicate site of abnormal blood accumulation. (D) Examples of 11.5 dpc embryos of genotypes shown exposed to tamoxifen in
utero 72 h earlier at 8.5 dpc. (E) 9.0 dpc embryos of genotypes shown exposed to tamoxifen in utero 48 h earlier at ~7.0 dpc. Bars=0.5 cm. (F) 12.5 dpc embryos of genotypes shown
exposed to tamoxifen in utero 48 h earlier. Boxed regions in (a) and (b) aremagniﬁed in (c) and (d), respectively. H&E stained sections of the embryo in (b) showing sites of bleeding
(arrows) in ganglion VIII (e) and lung primordia (f). Bars=0.5 cm (a–d) and 100 μm (e, f).
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Tie2-Cre animals were born, indicating that these mice die during
embryogenesis. Embryos were collected from these matings, and
while at 8.5 dpc the Tie2-Cre mutant embryos appeared indistin-
guishable from the control littermates, by 9.5 dpc approximately a
third of the mutant embryos appeared slightly developmentally
delayed and/or paler compared to the control embryos (Fig. 3A a, b).
The 9.5 dpc Tie2-Cre embryos were also stained for PECAM1 andwere
imaged by ﬂuorescent stereomicroscopy. The vessels in the heads of
the Tie2-Cre mutants lacked the well-deﬁned network of the controls,
and instead, the vascular plexus had a ﬂattened appearance, and the
diameter of the vessels was not uniform unlike that of control vessels
(Fig. 3B a,b; arrow and arrowhead). There was also variation in the
size of the spaces between ‘vessels’ (Fig. 3B a,b). There was noevidence of any obvious heart defect in these mutant embryos either
morphologically or histologically, and the hearts were beating at the
time of dissection (not shown). By 10.5 dpc, the mutant embryos
were dead or dying, often with evidence of severe haemorrhaging
(Fig. 3A d). It was apparent at both 9.5 dpc and 10.5 dpc that the yolk
sacs of the Tie2-Cre mutant embryos were much paler, thinner and
more fragile than the controls (Figs. 3A a,b and 6B). PECAM1 staining
of the 9.5 dpc yolk sacs highlighted defects in the vitelline vascular
network of the mutants (Fig. 3B c, d) where only remnants of
the major vessels were apparent. The vessels that were present
appeared to have degenerated, and PECAM1 staining was weaker
and abnormally distributed. This yolk sac phenotype was more
severe than generally observed in the tamoxifen-treated CreER
mutants.
Fig. 2. Tln1 CreER embryos show defective blood vessel organisation. (A) 10.5 dpc
embryos of genotypes shown were exposed in utero to tamoxifen at ~8.5 dpc and were
then sectioned and stained with antibody to the endothelial-speciﬁc marker,
endomucin (brown). Sections shown are of the lateral neural tube at the cervical
region. The mutant vessels are often not completely enclosed (arrow) and packed with
blood cells (*). In some areas blood cells can been seen outside the vessels (arrowhead).
Bars=50 μm. (B) 10.5 dpc Tln1ﬂ/ﬂ;CreER (mut) and Tln1ﬂ/+;CreER (con) embryos
exposed to tamoxifen in utero 48 h earlier were whole mount stained for PECAM1, then
imaged on a ﬂuorescent stereomicroscope; only boxed regions shown in left panels
are shown (a–d). The mutant vessels (b, d) are dilated (open arrowhead), dis-
continuous (arrow) and endothelial cells are not organised into vessels (arrowhead).
Bars=100 μm.
Fig. 3. Endothelial cell-speciﬁc deletion of Tln1 results in angiogenesis defects.
(A) Examples of 9.5 dpc (a, b) and 10.5 dpc (c, d) embryos of genotypes shown.
Bars=0.5 mm. (B) PECAM1 whole mount stained 9.5 dpc embryo heads of genotypes
shown (a, b) were imaged by ﬂuorescent stereomicroscopy. While the vessels in the
control (a) are uniform in size becoming narrower more distally, the vessels of the
mutant (b) show large variations in diameter with both dilated (arrow) and narrow
(arrowhead) vessels nearby one another. In the mutant there is also a variation in the
size of the spaces between vessels. 9.5 dpc yolk sacs (c, d) of genotypes shown were
also stained for PECAM1 and imaged by confocal microscopy; the maximum intensity
projections are shown. Bar=100 μm (a, b) and 200 μm (c,d).
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Since Tie2-Cre-mediated knockout of Tln1 in endothelial cells results
in a similar angiogenesis defect to that seen followingglobal inactivation
of Tln1 by CreER (compare Figs. 2B with 3B) it implied an endothelial
defect in both cases so we conjectured that endothelial cells may only
express talin1 and not the highly related talin2 isoform. To test this, we
used talin1 and talin2 isoform-speciﬁc antibodies on isolated primary
endothelial cells and conﬁrmed that indeed talin1was the only isoform
detectable in mouse lung endothelial cells (MLEC) by Western blotting
(Fig. 4A) and in embryonic endothelial cells by immunostaining
(Fig. 4B). Talin1 was detected in FAs throughout the endothelial cell
(Fig. 4B, left panel) whereas talin2 was detected only in FAs of the non-
endothelial cells (Fig. 4B, right panel, inset). Similarly, talin2 was not
expressed in primary human endothelial cells isolated from a range of
vessels types including arterial, venous andmicrovessels and nor was it
upregulated in talin1 knockdown endothelial cells (Kopp et al., 2010
and SJM unpublished data). The fact that endothelial cells only express
talin1 whereas both talin1 and talin2 are expressed in embryonicﬁbroblasts (Kopp et al., 2010) would explain the endothelial cell-
speciﬁc phenotype observed in the CreER mutant embryos exposed to
tamoxifen. As talin1 is the only isoform expressed in endothelial cells,
we usedMLEC to look at the effect of Tln1 knockout on the behaviour of
these cells in culture. MLEC from Tln1ﬂ/ﬂ;CreERmice were treated with
4OHT (or vehicle control) and stained 72 h later for talin1. The 4OHT
treated cells on glass coverslips were rounded and possessed no talin1-
containing FAs, while cells treated with the vehicle control were
ﬂattened and spread, and possessed talin1-containing FAs (Fig. 4C).
Endothelial cells lacking talin1 in vivo remain rounded and are unable to
organise into vessels
To determine how loss of talin1 affects behaviour of endothelial
cells in vivo, we looked closely at the morphology of the endothelial
Fig. 4. Talin1 is the only isoform expressed in endothelial cells and as such is necessary for cell spreading in vitro. (A) Western blots of lysates from two separate MLEC lines and
embryonic kidney probed with talin1 (T1) and talin2 (T2) speciﬁc antibodies. Vinculin (Vinc) was used as a loading control. (B) Primary embryonic endothelial cells cultured on
coverslips stained with antibodies to either talin1 (T1) or talin2 (T2) (green) along with antibodies to PECAM1 (red) and actin (blue). Talin2 was detected only in the PECAM
negative non-endothelial cells (inset). (C) MLEC from Tln1ﬂ/ﬂ;CreER mice were treated with either 100 nM 4OHT or ethanol and stained 72 h later for talin1 (green). Bars=20 μm.
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Tln1ﬂ/ﬂ;Tie2-Cre embryos. Confocal imaging of PECAM1 stained
embryos at high magniﬁcation allowed us to resolve the individual
endothelial cells that make up the newly forming vessels (Fig. 5A b, e).
In the control, the endothelial cells appeared large and ﬂattened into
tube-shaped vessels that enclosed a blood ﬁlled lumen (Fig. 5A b and
Supplementary video 1). Endothelial cells in the mutant embryos
were smaller and rounded (Fig. 5B e, arrows) and did not enclose a
lumen but rather formed a sheet of cells (Supplementary video2). In
contrast, the larger well-established vessels feeding the head region of
the mutant embryos were composed of large ﬂattened endothelial
cells enclosing a lumen comparable to controls (Fig. 5B c, f).
Transmission electron microscopy (TEM) was used to conﬁrm the
above observations. In order to identify the endothelial cells in the EM
sections, Tie2-Cre embryoswere used that possessed the ROAS26-lacZ
reporter (Soriano, 1999). These embryos were whole mount stained
with X-gal prior to processing for EM. This allowed β-gal positive
endothelial cells to be identiﬁed by their electron dense deposits of
bromo-chloro-indolyl-galactoside (Nakajima et al., 2003). In control
embryos, the vessels were composed of endothelial cells whose thin
membrane extensions surrounded embryonic nucleated blood cells
(Fig. 5B a, c). The endothelial cells comprising the vessels in the Tie2-
Cre mutants were rounded, and there were no signs of the thin
membrane protrusions. Again, as in the CreER mutant embryos, the
blood cells were often tightly packed into vessels (Fig. 5B b, d). In
summary, these results demonstrate for the ﬁrst time that talin1 is
required by endothelial cells in vivo to develop the spread mor-
phology that is crucial for their organisation into vessels.
The talin1 endothelial cell defect in vivo is rescued by expression of a
talin1 mini-gene
A mouse line expressing a GFP cDNA and a Tln1 mini-gene under
the control of the actin promoter was generated by pro-nuclear
injection. The construct was designed such that the Tln1mini-gene is
only expressed upon Cre deletion of the ﬂoxed stop cassette con-
taining the GFP cDNA (Fig. 6A). One line was chosen that expressed
GFP in a wide range of tissues (not shown). We demonstrated that the
transgene is also widely expressed in 9.5 dpc embryos as demon-
strated by GFP ﬂuorescence throughout the embryo (Fig. 6B). Crosses
were established to generate Tie2-Cre mutant mice either with orwithout the GFP/Tln1 transgene (Tg(GFP-Tln1).While the Tln1ﬂ/ﬂ;Tie2-
Cre embryos do not survive to 10.5 dpc the additional presence of
the GFP/Tln1 transgene in embryos was able to rescue the angio-
genesis defect and the Tln1ﬂ/ﬂ;Tie2-Cre;Tg(GFP-Tln1) embryos
appeared normal with no evidence of vessel defects (Fig. 6B). The
Tln1 transgene was even able to rescue the Tie2-Cre mutant mice to
birth, and 10 Tln1ﬂ/ﬂ;Tie2-Cre;Tg(GFP-Tln1) mice (compared to an
expected 9; p=0.15) were born that were viable and fertile and
appeared indistinguishable from their littermates.
Discussion
Tamoxifen-mediated global deletion of the Tln1 gene in 8.5 dpc
mouse embryos results in defects in blood vessel organisation 48 h
later. The vascular defect is sufﬁciently severe that these embryos are
not able to survive the subsequent 24 h (Fig. 1), presumably dying
from lack of nutrient and oxygen supply. The surprising speciﬁcity and
reproducibility of the vascular phenotype that resulted from deletion
of Tln1 throughout the embryo appears to be due to the fact that
endothelial cells, unlike other embryonic cells (Kopp et al., 2010) and
many adult tissues (Debrand et al., 2009; Monkley et al., 2001), only
express talin1, and there is no talin2 to compensate for loss of talin1.
The close similarity between the CreER and Tie2-Cre phenotypes
suggests that the vascular phenotype in CreER embryos is due
primarily to defects in endothelial cells that arise from loss of talin1.
There is a possibility that CreER-mediated deletion of Tln1 from other
cells such as pericytes/vascular smoothmuscle cells contributes to the
phenotype, but this is unlikely as the vascular defects occur in newly
forming vessels prior to the appearance of pericytes as determined by
α-smooth muscle actin expression (not shown). In addition, primary
aortic smooth muscle cells express both talin isoforms (Kopp,
Monkley and Critchley, unpublished data), and therefore would not
be expected to be affected by loss of talin1.
Numerous studies using both conditional and germline gene
knockout of various integrin subunits have provided evidence that
integrins play an important role in developmental angiogenesis,
although it has been difﬁcult to determine the contributions of
speciﬁc integrins to this process due to complex phenotypes, and
redundancy or compensation between certain integrin subunits
(Hynes, 2007; Silva et al., 2008). For example α5- and αV-integrins
have been shown to co-operate during vascular remodelling, but even
Fig. 5. Tln1 null endothelial cells are unable to spread and ﬂatten in vivo. (A) Confocal
maximum intensity projections of 9.5 dpc Tie2-Cre embryos whole mount stained for
PECAM1 (genotypes shown). Higher power views of the boxed regions in (a) and
(d) are shown in (b) and (c) and (e) and (f), respectively; Bars=200 μm (a, d) and
20 μm (b, c, e, f). (B) Electron micrographs of ultrathin sections through the heads of
X-gal stained 9.5 dpc embryos of genotypes shown. The endothelial cells (ec) and in
some cases the blood cells (bc; which can also express Tie2-Cre) are identiﬁable due
to the insoluble electron dense deposits of bromo-chloro-indolyl-galactoside product
that appear as black spots within the cells. Bar=5 μm.
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bryos are still able to form normal embryonic vasculature suggesting
that additional α-integrin(s) can contribute to the process (van der
Flier et al., 2010). Endothelial-speciﬁc deletion of β1-integrin
produced the earliest and most severe defects of all integrins causing
death of the embryos by 10.5 dpc (Carlson et al., 2008; Lei et al., 2008;
Tanjore et al., 2008). The Tie2-Cre/β1-integrin phenotypes are very
similar in nature and timing to the Tie2-Cre/talin1 phenotype
reported here, in line with the idea that talins are critical for
integrin-mediated adhesion. The absence of any vascular phenotype
prior to 9.5 dpc in either talin1 or β1-integrin Tie2-Cre knockout
embryos can be attributed to the delay between initial Tie2-Cre
expression and the subsequent depletion of talin1 or β1-integrin
protein. Evidence for this is provided here by the use of CreER to
inactivate Tln1 at 7.0 dpc in all endothelial cells (and precursors) prior
to the time when they would ﬁrst begin to express Tie2 (Kisanuki
et al., 2001). This resulted in vascular abnormalities at 9.0 dpc
(Fig. 1D) that were more severe than any observed with Tie2-Cre/
talin1 (or Tie2-Cre/β1-integrin) conﬁrming a role for talin1-mediated
adhesion events from the earliest stages of angiogenesis. However we
were unable to use this approach to investigate the role of talin1 in
angiogenesis/vasculogenesis any earlier than 7.0 dpc because of therequirement for talin1 during pre-gastrulation morphogenesis
(Monkley et al., 2000).
Inactivation of Tln1 over a range of embryonic ages using the
CreER/tamoxifen system has also allowed us to dissect more
thoroughly the role of talin1 in older embryos that have already
undergone signiﬁcant vascularisation. In doing so, we observed that
the later in development the tamoxifen was administered, the less
severe andmore localised the bleeding/vascular phenotype became. It
appears that within the ﬁrst 48 h following tamoxifen injection, Tln1
inactivation in endothelial cells only affects newly forming vessels,
while inactivation of Tln1 in endothelial cells in established vessels
had no apparent effect on vessel structure or integrity (Figs. 1F
and 5A). This observation was surprising and we initially considered
the possibility that talin1 may not required by endothelial cells once
they become organised into vessels. However a more likely explana-
tion is that endothelial cells in vessels have very stable cell–matrix
junctions, and talin1 protein persists in these junctions long after
deletion of the Tln1 gene. In contrast, endothelial cells that are actively
involved in angiogenesis and are thereby undergoing changes in cell
shape and polarity will be continually remodelling their cell–matrix
junctions, likely increasing the rate of talin1 protein turnover. As a
result, their talin1 protein stocks will be depleted more rapidly,
making these cells much more sensitive to inactivation of the Tln1
gene. This conclusion is supported by observations on Tln1 knockout
and knockdown cells in vitro where it can take at least 72 h following
CreER activation before talin1 protein levels are reduced sufﬁciently
to elicit changes in cell morphology (Fig. S1B and Kopp et al., 2010).
However trypsinisation and replating of the cells, which disrupts
adhesion complexes, facilitates the loss of talin1 as well as the
appearance of defects in cell spreading (Fig. S1C, arrows).
The function of talin has been studied extensively in cells in
culture, and it has become apparent that while talin1 is not required
for initial cell adhesion and cell spreading, it is required for cells to
maintain their spread morphology and for cell migration (Kopp et al.,
2010; Zhang et al., 2008). Here we describe for the ﬁrst time how talin
null cells behave in vivo. Visualisation of endothelial cells in Tln1ﬂ/ﬂ;
Tie2-Cre embryos by confocal microscopy and TEM show that these
endothelial cells are rounded and unable to ﬂatten and spread. The
phenotype of the talin1 null cells in vivo is very similar to that of
cultured endothelial cells (HUVEC) where knockdown of talin1
prevents focal adhesion formation, and as a result, the cells are
unable to maintain a spread morphology. In addition, talin1
knockdown in HUVEC also leads to defects in cell migration (Kopp
et al., 2010). Based on these observations, we conclude that in the
absence of talin1, endothelial cells in vivo cannot form the cell–matrix
junctions required to adopt the ﬂattened morphology found in
vessels. Additionally the morphology of Tln1ﬂ/ﬂ;Tie2-Cre endothelial
cells in electron micrographs (Fig. 5B) bears considerable similarity to
those in a recent report in which it was shown that β1-integrin is
required to establish endothelial cell polarity and lumen formation
(Zovein et al., 2010). This raises the possibility that talin1 (via β1-
integrins) may play a role in these processes as well.
Why endothelial cells, like cells of the haematopoetic lineage such
as platelets and dendritic cells express only talin1 (Lämmermann
et al., 2008; Petrich et al., 2007) is unclear. Endothelial cells and
haematopoetic cells arise from the same progenitor cells, the
haemangioblast, during embryonic development (Pardanoud et al.,
1989). EST data suggest that both talin isoforms are widely expressed
prior to this suggesting that talin2 is speciﬁcally turned off in cells of
this lineage. The Tln2 promoter lies within a CpG island (Debrand
et al., 2009) raising the possibility that it could be transcriptionally
repressed by methylation. Consistent with this idea, down-regulation
of talin1 in endothelial cells in vitro does not lead to upregulation of
talin2 (unlike in mouse embryo ﬁbroblasts) (Kopp et al., 2010), and
thus talin1-deﬁcient endothelial cells show defects in cell spreading,
migration and FA assembly. As such endothelial cells provide a system
Fig. 6. A Tln1mini-gene can rescue Tie2-Cre-mediated loss of Tln1 in embryos. (A) Construct used to generate a transgenic line (Tg(Gfp-Tln1)) expressing GFP and Cre-inducible Tln1
mini-gene. (B) 10.5 dpc embryos of genotypes shown were imaged on a stereomicroscope either under bright ﬁeld (left) or GFP ﬂuorescent illumination (right). Fluorescently
imaged embryo shows widespread expression of GFP encoded by the transgene. The Tln1ﬂ/ﬂ;Tie2-Cre embryo at the bottom does not possess the GFP transgene and so no ﬂuorescent
image is shown.
501S.J. Monkley et al. / Developmental Biology 349 (2011) 494–502well-suited to conduct detailed structure/function analysis of talin1 in
vitro (Kopp et al., 2010) and ultimately, in vivo.
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